Detalhe da pesquisa
1.
Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR-mutated lung cancer treated with the first-/second-generation tyrosine kinase inhibitors.
J Pathol Clin Res
; 10(2): e354, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38284983